Search

Your search keyword '"Morilla, Alison"' showing total 39 results
Start Over Author "Morilla, Alison"
39 results on '"Morilla, Alison"'

1. Contributors

Author

Bain, Barbara J., primary, Bates, Imelda, additional, Bradshaw, Anne E., additional, Briggs, Carol, additional, Burthem, John, additional, Cantwell, Carol, additional, Carter, Jane Y., additional, De la Salle, Barbara, additional, Foroni, Letizia, additional, Gerrard, Gareth, additional, Harrington, Dominic J., additional, Hing, Sandra, additional, Laffan, Michael A., additional, Layton, Mark, additional, Mitchell Lewis, S., additional, Manning, Richard A., additional, May, Alison M., additional, McNamara, Christopher, additional, Milkins, Clare, additional, Morilla, Ricardo, additional, Morilla, Alison M., additional, Nadal-Melsió, Elisabet, additional, Nijran, Kuldip S., additional, Osei-Bimpong, Andrew, additional, Perry, David J., additional, Regan, Fiona A.M., additional, Reid, Alistair G., additional, Richards, Stephen J., additional, Robertson, Lynn D., additional, Roper, David, additional, Rowley, Megan, additional, Thachil, Jecko, additional, Toma, Sarmad, additional, Wild, Barbara J., additional, Win, Nay, additional, and Worwood, Mark, additional

Published
2017
Full Text
View/download PDF

4. Contributors

Author

Bain, Barbara J., primary, Bates, Imelda, additional, Blackmore, Sheena, additional, Bradshaw, Anne E., additional, Briggs, Carol, additional, Burthem, John, additional, Cantwell, Carol, additional, Carter, Jane Y., additional, Cotton, Peter Charles, additional, Foroni, Letizia, additional, Hamilton, Malcolm S., additional, Jury, Corrine L., additional, Kaeda, Jaspal, additional, Laffan, Michael A., additional, Layton, Mark, additional, Lewis, S. Mitchell, additional, Manning, Richard A., additional, Matutes, Estella, additional, May, Alison, additional, Milkins, Clare, additional, Morilla, Ricardo, additional, Morilla, Alison M., additional, Nagai, Yutaka, additional, Nijran, Kuldip S., additional, Osei-Bimpong, Andrew, additional, Regan, Fiona A.M., additional, Roper, David, additional, Rowley, Megan, additional, Swirsky, David, additional, Tatsumi, Noriyuki, additional, Vives-Corrons, Joan-Lluis, additional, Vulliamy, Thomas J., additional, West, Mary A., additional, Wild, Barbara J., additional, Win, Nay, additional, and Worwood, Mark, additional

Published
2012
Full Text
View/download PDF

11. (zeta)-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia

Author

Del Giudice, Ilaria, Morilla, Alison, Osuji, Nnenna, Matutes, Estella, Morilla, Ricardo, Burford, Anna, Maravelaki, Sonia, Owusu-Ankomah, Kwasi, Swansbury, John, A'Hern, Roger, Brito-Babapulle, Vasantha, and Catovsky, Daniel

Subjects
Cancer patients -- Prognosis, Chronic lymphocytic leukemia -- Care and treatment, Chronic lymphocytic leukemia -- Genetic aspects, Gene expression -- Analysis, Gene mutations -- Analysis, Cancer -- Care and treatment, Cancer -- Genetic aspects, Health
Published
2005

15. Inter-laboratory validation of a harmonized PNH flow cytometry assay

Author

Payne, Daniel, primary, Johansson, Ulrika, additional, Bloxham, David, additional, Couzens, Stephen, additional, Carter, Anthony, additional, Holtom, Pamela, additional, Baker, Bronia, additional, Hughes, Mark, additional, Knill, Tara, additional, Milne, Tim, additional, Morilla, Alison, additional, Morilla, Ricardo, additional, O'Brien, David, additional, and Thomas, Lisa, additional

Published
2018
Full Text
View/download PDF

16. High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).

Author

Mehra, Niven, primary, Morilla, Ricardo Marcelo, additional, Sharp, Adam, additional, Morilla, Alison, additional, Crespo, Mateus, additional, Lambros, Maryou B., additional, Thomas, Karen, additional, Nava Rodrigues, Daniel, additional, Bianchini, Diletta, additional, Flohr, Penelope, additional, Dearnaley, David P., additional, Parker, Chris C., additional, and De Bono, Johann S., additional

Published
2016
Full Text
View/download PDF

21. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL

Author

Morilla, Alison, primary, Gonzalez de Castro, David, additional, Del Giudice, Ilaria, additional, Osuji, Nnenna, additional, Else, Monica, additional, Morilla, Ricardo, additional, Brito Babapulle, Vasantha, additional, Rudenko, Hannah, additional, Matutes, Estella, additional, Dearden, Claire, additional, Catovsky, Daniel, additional, and Morgan, Gareth J, additional

Published
2008
Full Text
View/download PDF

22. Immunoglobulin Gene Translocations Are Frequent in Unclassifiable CD5+ Small B-Cell Leukemias and in Particular, a Novel Subtype Characterised by t(14;19)(q32;q13) and Deregulation of BCL3 Is Described.

Author

Morilla, Alison, primary, Martin, Paloma, additional, Min, Toon, additional, Morilla, Ricardo, additional, Remstein, Ellen, additional, Gonzalez, David, additional, Dearden, Claire, additional, Morgan, Gareth J., additional, and Matutes, Estella, additional

Published
2007
Full Text
View/download PDF

25. Prognostic Factors in the UK LRF CLL4 Trial.

Author

Oscier, David Graham, primary, Wade, Rachel, additional, Orchard, Jenny, additional, Davis, Zadie, additional, Best, Giles, additional, Morilla, Alison, additional, Brito-Bapapulle, Vasantha, additional, Matutes, Estella, additional, Richards, Sue, additional, and Catovsky, Daniel, additional

Published
2006
Full Text
View/download PDF

26. Evaluation of ZAP‐70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process

Author

Letestu, Remi, primary, Rawstron, Andy, additional, Ghia, Paolo, additional, Villamor, Neus, additional, Leuven, Nancy Boeckx, additional, Boettcher, Sebastian, additional, Buhl, Anne Mette, additional, Duerig, Jan, additional, Ibbotson, Rachel, additional, Kroeber, Alexander, additional, Langerak, Anton, additional, Le Garff‐Tavernier, Magali, additional, Mockridge, Ian, additional, Morilla, Alison, additional, Padmore, Ruth, additional, Rassenti, Laura, additional, Ritgen, Matthias, additional, Shehata, Medhat, additional, Smolewski, Piotr, additional, Staib, Peter, additional, Ticchioni, Michel, additional, Walker, Clare, additional, and Ajchenbaum‐Cymbalista, Florence, additional

Published
2006
Full Text
View/download PDF

27. Prognostic Factors in the UK LRF CLL4 Trial.

Author

Oscier, David Graham, primary, Richards, Sue, additional, Orchard, Jenny, additional, Davis, Zadie, additional, Best, Giles, additional, Morilla, Alison, additional, Brito-Bapapulle, Vasantha, additional, Matutes, Estella, additional, Pettitt, Andrew, additional, and Catovsky, Daniel, additional

Published
2005
Full Text
View/download PDF

34. p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53deletion and resistance to fludarabine

Author

Martin, Paloma, Attygalle, Ayoma, Swansbury, John, Min, Toon, Morilla, Alison, Hockley, Sarah, Wotherspoon, Andrew, Morgan, Gareth, Catovsky, Daniel, Dearden, Claire, and Matutes, Estella

Abstract

Abnormalities of the TP53gene in chronic lymphocytic leukaemia (CLL) are associated with large cell transformation, short survival and resistance to purine analogue therapy. Deletion of one allele and somatic mutation of the remaining allele have been described as the main mechanism of TP53inactivation in CLL, but its relationship with p53 protein expression remains unclear. We studied 103 CLL patients using fluorescence in situ hybridisation (FISH) to detect allelic loss at chromosome 17p and immunohistochemistry (IHC) to test for p53 protein overexpression. TP53deletion (≥10% of cells) was found in 21 cases (20.4%) and no deletion in 82 (79.6%). By IHC, 16 cases (15.5%) showed p53 protein expression and 87 (84.5%) were negative. There was a good correlation between FISH and IHC in 86 cases (83.5%; p< 0.001) and these comprised ten cases positive for both assays and 76 negative cases. The remaining 17 cases had discrepant results: 11 cases showed TP53deletion and were p53 negative, and six cases had strong expression of protein and no TP53deletion (FISH). Seventy-two patients (70%) received fludarabine. The majority (86%) of patients without abnormalities of TP53responded to fludarabine and only eight cases were resistant. Within the rest, all patients positive with both methods were refractory, 60% of cases with overexpression without deletion and 40% of cases with deletion without protein overexpression were non-responders to fludarabine. Our findings indicate that IHC is a simple method and provides useful complementary information to FISH analysis for the evaluation of TP53dysfunction. Both methods can be carried routinely to identify patients with a high chance to be resistant to fludarabine containing regimens (p= 0.0003).

Published
2010
Full Text
View/download PDF

35. Mechanically Disaggregated Unfixed Trephine Biopsies Can be Used for Diagnostic Immunophenotyping in Acute Leukaemia

Author

Taussig, David, Morilla, Ricardo, Morilla, Alison, Moss, Kate, Nikolova, Veselka, Marquardt, Kelly, Duke, Sophie, Adamowska, Kasia, Fuller, Lynnsay, Taifoor, Ala, Johnson, Naomi, Zeisig, Athanasia, and Atra, Ayad

Abstract

An adequate bone marrow sample is essential for a rapid diagnosis of acute leukaemia by multicolour flow cytometry enabling the assignment of lineage and choice of therapy.

Published
2017
Full Text
View/download PDF

37. Contributors

Author

Bain, Barbara J., Bates, Imelda, Blackmore, Sheena, Bradshaw, Anne E., Briggs, Carol, Burthem, John, Cantwell, Carol, Carter, Jane Y., Catovsky, Daniel, Cotton, Peter C., Foroni, Letizia, Hamilton, Malcolm S., Jury, Corrine L., Kaeda, Jaspal, Laffan, Michael, Layton, Mark, Lewis, S. Mitchell, Manning, Richard A., Matutes, Estella, May, Alison, Milkins, Clare, Morilla, Ricardo, Morilla, Alison M., Nagai, Yutaka, Nijran, Kuldip S., Osei-Bimpong, Andrew, Regan, Fiona A.M., Roper, David, Rowley, Megan, Swirsky, David, Tatsumi, Noriyuki, Vives-Corrons, Joan-Lluis, Vulliamy, Thomas J., West, Mary A., Wild, Barbara J., Win, Nay, and Worwood, Mark

Full Text
View/download PDF

38. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Author

Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, and Catovsky D

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Female, Humans, Male, Middle Aged, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell pathology
Abstract

Background: Many prognostic markers have been identified in chronic lymphocytic leukemia, but there have been few opportunities to assess their relative importance in a large randomized trial. The aim of this study was to determine which of the available markers independently predicted outcome in patients requiring treatment and to use these to define new risk groups., Design and Methods: A broad panel of clinical and laboratory markers, measured at randomization in patients entering the LRF CLL4 trial, was assessed with respect to treatment response, progression-free and overall survival, at a median follow-up of 68 months., Results: Using the factors identified as independent predictors for progression-free survival, patients were subdivided into three risk groups: 6% had poor risk with known TP53 loss of greater than 10%; 72% had an intermediate risk without TP53 loss (≤ 10%) and with at least one of: unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4 mg/L; 22% had a good risk (with none of the above and mutated IGHV genes). The 5-year progression-free survival rates for these three groups were 0%, 12% and 34%, respectively, and the corresponding 5-year overall survival rates were 9%, 53% and 79% (both P<0.00005 independent of treatment allocation). In the intermediate risk group 250 patients, with data for all three risk factors, were further subdivided into intermediate-low (one risk factor) or intermediate-high (2 or 3 risk factors). The 5-year progression-free survival rates were 18% and 7% (P=0.0001) and the 5-year overall survival rates were 68% and 40% (P<0.00005), respectively., Conclusions: This study demonstrates the role of biomarkers in prognosis and shows that, in patients requiring treatment, disease stage may no longer be an independent predictor of outcome. If validated independently, the risk groups defined here may inform the design of future trials in chronic lymphocytic leukemia.

Published
2010
Full Text
View/download PDF

39. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes.

Author

Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A'Hern R, Delgado J, Bazerbashi MB, and Catovsky D

Subjects
Antibodies, Monoclonal immunology, Biomarkers, Tumor immunology, Flow Cytometry, Humans, Immunophenotyping, Interleukin-3 Receptor alpha Subunit, Leukemia, Hairy Cell immunology, Leukemia, Hairy Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Lymphocytes pathology, Lymphoma, B-Cell metabolism, Receptors, Interleukin-3 immunology, Sensitivity and Specificity, Splenic Neoplasms immunology, Splenic Neoplasms metabolism, Biomarkers, Tumor biosynthesis, Leukemia, Hairy Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Lymphocytes metabolism, Lymphoma, B-Cell diagnosis, Receptors, Interleukin-3 biosynthesis, Splenic Neoplasms diagnosis
Abstract

Background and Objectives: CD123 is an antibody that identifies the a chain of the human interleukin-3 receptor and is expressed in a variety of normal hematopoietic cells, acute leukemia and hairy cell leukemia (HCL). The aim of the study was to investigate the diagnostic value of CD123 expression in B-cell disorders with circulating hairy and villous lymphocytes., Design and Methods: We investigated the diagnostic value of CD123 expression in neoplastic cells from 59 patients with B-cell disorders with circulating hairy or villous lymphocytes: HCL (n=24), the variant form of HCL (n=11) and splenic lymphoma with villous lymphocytes (SLVL) (n=24). Cells from 12 patients with chronic lymphocytic leukemia were used as controls. Immunophenotypic analysis was performed by flow cytometry on 77 samples from peripheral blood (n=48), bone marrow (n=25) and spleen cell suspensions (n=4)., Results: Our findings show that cells from 95% of typical HCL express CD123 with strong to moderate intensity while this molecule is absent in circulating cells from most cases of HCL-variant (91%) and SLVL (97%)., Interpretation and Conclusions: We conclude that CD123 is a useful new marker for distinguishing B-cell disorders with circulating villous lymphocytes as its expression is characteristic of typical HCL with high sensitivity and specificity. However CD123 does not allow the distinction between HCL-variant and SLVL, as both are CD123 negative.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results